2015 Fiscal Year Final Research Report
The development of novel biomarker and treatment for renal cell carcinoma based on the assessment by FDG PET/CT
| Project/Area Number |
25462494
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
NAKAIGAWA Noboru 横浜市立大学, 医学(系)研究科(研究院), 准教授 (00237207)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAO Masahiro 横浜市立大学, 医学研究科, 教授 (00260787)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 腎細胞癌 / 血液マーカー / 治療効果判定 / 分子標的治療 / FDG PET/CT |
|---|
| Outline of Final Research Achievements |
We previously reported the possibility of FDG PET/CT as an imaging biomarker to assess the response of renal cell carcinoma (RCC) to molecular-targeted therapy simultaneously, which was difficult to judge by conventional computed tomographic scanning. FDG PET/CT has some problems including cost and radiation exposure, and the blood biomarker which can be examined easily and safely was desired. In this study, we isolated the blood biomarker to assess the response of renal cell carcinoma to molecular-targeted therapy, by analyzing the blood samples form the patients with RCC treated by molecular-targeted therapy and monitored by FDG PET/CT.
|
| Free Research Field |
泌尿器科学
|
